Why Your State Is Costing You Remote Jobs And What To Do About It
If you’ve been on the hunt for a remote job and feel like you’re hitting a brick wall, the culprit might just be your state. This article dives into how…
EHRC: Interim update on single-sex spaces draws criticism
The Equality and Human Rights Commission (EHRC) has stirred up quite a bit of debate with its recent interim update regarding single-sex spaces. The update, following a landmark ruling by…
How can HR battle the rise in identity fraud?
HR teams and recruiters are up against a serious challenge as identity fraud continues to rise, fuelled by sophisticated AI tools. With over 237,000 reported cases in 2023, it’s imperative…
How Big Tech’s AI Layoffs Are Creating the Next Great Wealth Wave
Something peculiar is on the rise in Big Tech. Amidst sweeping layoffs, companies are simultaneously rolling out shiny new AI tools promising to enhance productivity. What’s really going on here?…
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Summary Merck (NYSE: MRK) has announced positive findings from the Phase 3 KEYNOTE-689 trial, which evaluated the use of KEYTRUDA® (pembrolizumab) as a perioperative treatment for patients with locally advanced…